Aqilion is a biotech company that focuses on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions, such as autoimmune diseases. Mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials running development programs in close collaboration with selected partners with specific expertise in drug development.
The company runs four different programs which focus on developing novel, innovative treatments for chronic inflammatory diseases for which few or no treatments are available and where there is currently a clear patient need. The program closest to the clinical phase, Regulus, is based on a selective inhibitor of janus kinase 1 (JAK1) and will first be evaluated for the treatment of eosinophilic esophagitis (EoE), an inflammatory disease of the oesophagus for which there is a great need for new treatment options.
